ArticleHepatology (Baltimore, Md.)2021
E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1.Annals of surgical oncology · 2026Trial
- Non-Invasive Transdermal Delivery of miR-30a-5p via MUC1-Aptamer-Guided Tetrahedral DNA Nanostructures for Gene Silencing in Cutaneous Melanoma.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Correlation between E2F7 overexpression and immune infiltration in lung adenocarcinoma.Discover oncology · 2026Article
- Vacuolar Protein Sorting 35 Controls Hepatocellular Proliferation Through SRC Signaling and Promotes Diethyl Nitrosamine-Induced Tumor Initiation.Cellular and molecular gastroenterology and hepatology · 2026Article
- Systematic decoding of functional enhancer connectomes and risk variants in human glioma.Nature cell biology · 2025Article
- Ascending E2F7a/b ratio facilitates KLF13 transcription in hepatocellular carcinoma and correlates with the abundance of binuclear hepatocytes (ABH) modulation for short-term recurrence.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B.PloS one · 2025Article
- Review
- Integrated analysis reveals critical cisplatin-resistance regulators E2F7 contributed to tumor progression and metastasis in lung adenocarcinoma.Cancer cell international · 2024Article
- VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner.The Journal of biological chemistry · 2023Article
- Systematic analysis of the prognosis and immune infiltration of E2Fs in thyroid carcinoma.Frontiers in genetics · 2023Article
- E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription.Molecular carcinogenesis · 2022Article
- Comprehensive bioinformatics analysis of the E2F family in human clear cell renal cell carcinoma.Oncology letters · 2022Article
- Wnt signaling regulates hepatocyte cell division by a transcriptional repressor cascade.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53.Oncogene · 2022Article
- CircLATS2 Regulates miR-520a-3p/E2F7/p-VEGFR2 Signaling Pathway to Promote Hepatocellular Carcinoma Progression and Angiogenesis.Journal of oncology · 2022Article
- Comprehensive analysis of the functional and prognostic value of E2F transcription factors in human prostate cancer through data mining and experimental validation.Translational cancer research · 2021Article
- Review
- Atypical E2Fs either Counteract or Cooperate with RB during Tumorigenesis Depending on Tissue Context.Cancers · 2021Article
- Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Clear Cell Renal Cell Carcinoma.Journal of healthcare engineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsUp-regulation of the E2F-dependent transcriptional network has been identified in nearly every human malignancy and is an important driver of tumorigenesis. Two members of the E2F family, E2F7 and E2F8, are potent repressors of E2F-dependent transcription. They are atypical in that they do not bind to dimerization partner proteins and are not controlled by retinoblastoma protein. The physiological relevance of E2F7 and E2F8 remains incompletely understood, largely because tools to manipulate their activity in vivo have been lacking. APPROACH AND
resultsHere, we generated transgenic mice with doxycycline-controlled transcriptional activation of E2f7 and E2f8 and induced their expression during postnatal development, in adulthood, and in the context of cancer. Systemic induction of E2f7 and, to lesser extent, E2f8 transgenes in juvenile mice impaired cell proliferation, caused replication stress, DNA damage, and apoptosis, and inhibited animal growth. In adult mice, however, E2F7 and E2F8 induction was well tolerated, yet profoundly interfered with DNA replication, DNA integrity, and cell proliferation in diethylnitrosamine-induced liver tumors.
conclusionCollectively, our findings demonstrate that atypical E2Fs can override cell-cycle entry and progression governed by other E2F family members and suggest that this property can be exploited to inhibit proliferation of neoplastic hepatocytes when growth and development have subsided during adulthood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.